Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-collagen-4-SN-38
- Development stage
- Preclinical
- Lead developer
- National Cancer Center Hospital East
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
**anti-collagen-4-SN-38** is an experimental cancer-stroma-targeting antibody-drug conjugate developed as part of cancer stromal targeting therapy. It consists of an anti-collagen type IV monoclonal antibody conjugated through a PEGylated ester linker to SN-38, a topoisomerase I inhibitor. The conjugate binds collagen type IV within tumor stroma, forming a local drug depot that releases SN-38 extracellularly under physiological conditions; released SN-38 diffuses through stromal-rich tumor tissue and damages tumor cells and tumor vasculature. It showed preclinical antitumor activity in stroma-rich pancreatic cancer xenograft models. ([europepmc.org](https://europepmc.org/article/MED/21749132))
- Other names
- anti-collagen 4 SN-38 immunoconjugateanti-collagen4 SN-38 immunoconjugateanti-collagen-4 SN-38 immunoconjugateanti-collagen IV SN-38 immunoconjugateanti-collagen IV-SN-38 immunoconjugateanti-collagen-4-SN-38anti-collagen4-SN-38anti-collagen 4-SN-38
02
Targets
COL1 (Collagen type I)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on anti-collagen-4-SN-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-collagen-4-SN-38.